MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 8-19, 2020.
Article
in English
| WPRIM
| ID: wpr-877973
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, placing an increasing burden on human health. NAFLD is a complex multifactorial disease involving genetic, metabolic, and environmental factors. It is closely associated with metabolic syndrome, obesity, and type 2 diabetes, of which insulin resistance is the main pathophysiological mechanism. Over the past few decades, investigation of the pathogenesis, diagnosis, and treatments has revealed different aspects of NAFLD, challenging the accuracy of definition and therapeutic strategy for the clinical practice. Recently, experts reach a consensus that NAFLD does not reflect the current knowledge, and metabolic (dysfunction) associated fatty liver disease (MAFLD) is suggested as a more appropriate term. The new definition puts increased emphasis on the important role of metabolic dysfunction in it. Herein, the shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy of the newly defined MAFLD, as compared with the formerly defined NAFLD, are reviewed for updating our understanding.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Insulin Resistance
/
Metabolic Syndrome
/
Diabetes Mellitus, Type 2
/
Non-alcoholic Fatty Liver Disease
/
Obesity
Type of study:
Diagnostic study
/
Screening study
Limits:
Humans
Language:
English
Journal:
Chinese Medical Journal
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS